Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
NOVARTIS NEW ZEALAND LIMITED,Onasemnogene abeparvovec,"Spinal muscular atrophy (SMA), pre-symptomatic or type 1",Onasemnogene abeparvovec (ZOLGENSMA),Options for investment,Hospital,Nervous System
